Company Information

  

Address: 2200 PENNSYLVANIA AVE NW
SUITE 300E 
City: WASHINGTON 
State: DC 
Zip Code: 20037 
Telephone: 202-734-3400 

Description of Business

Primary SIC Code: 2834
(As filed with the SEC)  

Vanda Pharmaceuticals Inc. (we, our, the Company or Vanda) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. Vanda commenced its operations in 2003 and our product portfolio includes: * HETLIOZĀ® (tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), was approved by the U.S. Food and Drug Administration (FDA) in January 2014 and launched commercially in the U.S. in April 2014. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZĀ® for the treatment of Non-24 in totally blind adults. HETLIOZĀ® was commercially launched in Germany in August 2016.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
03/2018-0.12NAN/E
12/2017-0.35NAN/E
09/2017-0.32NAN/E
06/2017-0.23NAN/E
03/2017-0.29NAN/E
12/2016-0.41NAN/E
09/2016-0.25NAN/E
06/2016-0.47NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.03Total Liab/Total Assets0.36
Net Inc/Total Assets-0.08Total Liab/Inv Cap0.69
Net Inc/Inv Cap-0.14Total Liab/Comm Equity0.15
Pretax Inc/Net Sales-0.09Interest Coverage RatioNA
Net Inc/Net Sales-0.09Curr Debt/Equity0.21
Cash Flow/Net Sales-0.01LTD/EquityNA
SG&A/NetSales0.75Total Debt/Equity0.21
Asset Utilization   Liquidity  
Net Receivables Turnover8.72Quick Ratio2.40
Inventory Turnover22.05Current Ratio2.41
Inventory Day Sales0.06Net Rec/Curr Assets0.10
Net Sales/Work Cap1.66Inv/Curr Assets0.00
Net Sales/PP&E17.38  

Income Statement (Millions)

  3/31/2018 12/31/2017 9/30/2017 6/30/2017
Total Revenues(Net Sales) 43.59 44.28 41.34 42.06
Cost of Goods Sold 4.56 4.79 4.53 4.53
Selling & Admin Exps 26.82 31.05 31.12 31.37
Operating Income 2.44 -2.15 -4.92 -1.92
Interest Exp NA NA NA NA
Pretax Income 3.06 -1.75 -4.53 -1.53
Other Income 0.62 0.40 0.40 0.40
Net Income Bef Extraordinary ... NA NA NA NA
Net Income 3.07 -1.84 -4.55 -1.53

Balance Sheet (Millions)

Assets 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Cash & Short Term Investments 248.83 143.41 139.88 137.12
Receivables - Total 23.31 17.60 18.18 21.02
Inventories - Total 1.01 0.84 0.92 0.74
Total Current Assets 282.44 169.86 169.72 174.61
Net Property, Plant & Equipment 9.16 9.50 9.49 9.13
Total Assets 317.32 205.43 205.71 210.67
Liabilities        
Accounts Payable 17.24 43.36 44.54 50.44
Debt in Current Liabilities 27.00 27.00 27.00 25.00
Total Current Liabilities 71.96 70.36 71.54 75.44
Long-Term Debt NA 0.00 0.00 0.00
Total Liabilities 76.17 74.04 75.24 79.25
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.05 0.05 0.05 0.05
Retained Earnings -358.36 -361.43 -359.59 -355.04
Treasury Stock NA NA NA NA
Total Stockholders' Equity 241.14 131.39 130.47 131.42
Total Liabilities and Stockholders' Equity 317.32 205.43 205.71 210.67

Cash Flow Summary (Millions)

Categories 3/31/2018 12/31/2017 9/30/2017 6/30/2017
Net Cash Provided by Operating Activities 1.64 3.47 2.17 -2.26
Net Cash Provided by Investing Activities 16.31 7.49 5.40 -5.83
Net Cash Provided by Financing Activities 103.73 0.08 0.77 2.19

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201333.88-21.06-0.67
12/201450.1620.190.55
12/2015109.92-39.86-0.94
12/2016146.02-18.01-0.41
12/2017165.08-15.57-0.35
Growth Rates48.57----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional06/30/1815248,89993.84




Report Date : 7/16/2018

Powered By Edgar Online © 2018EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.